株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

遺伝子治療薬のR&Dと収益予測:癌、心血管疾患、希少疾患、眼科疾患など

Gene Therapy R&D and Revenue Forecasts 2017-2027: Cancer, Cardiovascular, Rare Diseases, Ophthalmologic, Other Diseases

発行 Visiongain Ltd 商品コード 351066
出版日 ページ情報 英文 127 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=156.58円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
遺伝子治療薬のR&Dと収益予測:癌、心血管疾患、希少疾患、眼科疾患など Gene Therapy R&D and Revenue Forecasts 2017-2027: Cancer, Cardiovascular, Rare Diseases, Ophthalmologic, Other Diseases
出版日: 2017年08月02日 ページ情報: 英文 127 Pages
概要

当レポートでは、世界の遺伝子治療市場について調査分析し、概要、主な治療薬と予測、二次市場、主要企業、R&Dパイプライン分析と予測など、体系的な情報を提供しています。

第1章 レポート概要

第2章 遺伝子治療の概要

  • 遺伝子治療とは
  • 遺伝子治療のタイプ
  • レポート除外製品
  • 遺伝子治療ベクトル

第3章 世界の遺伝子治療市場:主な治療薬と予測

  • 世界の遺伝子治療市場:製品の概要
  • Gendicine (rAd-p53)
  • Oncorine
  • Neovasculgen
  • Glybera

第4章 世界の遺伝子治療市場と疾患二次市場

  • 世界の遺伝子治療薬市場
  • 遺伝子治療市場の予測
  • 癌の遺伝子治療
  • 希少疾患の遺伝子治療
  • 心血管疾患の遺伝子治療
  • 眼科疾患の遺伝子治療
  • その他の疾患の遺伝子治療
  • 市場シェアの変化

第5章 遺伝子治療市場の注目企業

  • UniQure
  • Biogen
  • Bluebird Bio
  • Spark Therapeutics
  • Applied Genetic Technologies Corporation
  • Oxford Biomedica
  • GenSight Biologics
  • 遺伝子治療と大手製薬会社

第6章 R&Dパイプライン分析と予測

  • パイプライン
  • パイプライン分析
  • GSK2696273:GSK
  • Collategene (AMG0001):AnGes MG/Vical
  • BC-819:BioCancell
  • BC-821:BioCancell
  • Lenti-D:Bluebird Bio
  • LentiGlobin (LentiGlobin BB305):Bluebird Bio
  • SPK-RPE65:Spark Therapeutics
  • SPK-CHM:Spark Therapeutics
  • SPK-FIX:Spark Therapeutics/Pfizer
  • SPK-TPP1:Spark Therapeutics
  • Invossa (TissueGene-C):TissueGene Inc/Kolon Life Science
  • VM202-DPN:ViroMed
  • 重要なパイプライン技術開発
  • 遺伝子治療パイプラインの将来

第7章 遺伝子治療市場の定性分析

  • SWOT分析
  • 主要国市場

第8章 結論

付録

目次
Product Code: PHA0220

The gene therapy market is projected to grow at a CAGR of 40.8% in the first half of the forecast period. In 2016, the cancer treatment submarket accounted for 75.0% of the gene therapy drug market. Visiongain estimated that gene therapy for rare diseases will be the driver for market growth in the second half of the forecast period.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand-new 127 page report you will receive 70 charts - all unavailable elsewhere.

The 127-page report provides clear detailed insight into the gene therapy market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

image1

Report Scope

  • Gene Therapy market forecasts from 2017-2027
  • This report assesses the approved gene therapy products in the market and gives revenue to 2027 for Neovasculgen
  • Provides qualitative analysis and forecast of the submarket by indication for the period 2017-2027:
  • Cancer
  • Cardiovascular disorders
  • Rare diseases
  • Ophthalmological diseases
  • Other therapeutic uses
  • Profiles leading companies that will be important in the development of the gene therapy market. For each company, developments and outlooks are discussed and companies covered in this chapter include:
  • UniQure
  • Biogen
  • Bluebird Bio
  • Spark Therapeutics
  • Applied Genetics Technologies Corporation
  • Oxford Biomedica
  • GenSight Biologics
  • Assesses the outlook for the leading gene treatment R&D pipeline for 2016 and discusses technological progress and potential. Profiles appear for gene therapy drug candidates, with revenue forecasts for six leading agents:
  • SPK-RPE65 (Spark Therapeutics)
  • Collategene (AMG0001, AnGes MG/Vical)
  • Invossa (TissueGene-C, TissueGene Inc/Kolon Life Science)
  • BC-819 (BioCancell)
  • Lenti-D (Bluebird Bio)
  • GSK2696273 (GlaxoSmithKline)
  • Provides qualitative analysis of trends that will affect the gene therapies market, from the perspective of pharmaceutical companies, during the period 2017 to 2027. SWOT analysis is provided and an overview of regulation of the gene therapy market by leading region given.
  • Our study discusses factors that influence the market including these:
  • Translation of research into marketable products modifying human DNA - gene transfer for therapeutic use, altering the nuclear genome
  • Genomic editing technology and other supporting components
  • Collaborations to develop and launch gene-based products - acquisitions and licensing deals
  • Supporting technologies for human genetic modification, gene replacement and targeted drug delivery
  • Gene therapies for ophthalmologic diseases - next-generation medicines
  • Regulations in the United States, the European Union and Japan - overcoming technological and medical challenges to pass clinical trials.

Visiongainés study is intended for anyone requiring commercial analyses for the gene therapy market. You find data, trends and predictions.

Table of Contents

1. Report Overview

  • 1.1 Global Gene Therapy Market Overview
  • 1.2 Benefits of This Report
  • 1.3 How This Report Delivers
  • 1.4 Key Questions Answered by This Analytical Report
  • 1.5 Who is This Report For?
  • 1.6 Methods of the Study
  • 1.7 Frequently Asked Questions (FAQ)
  • 1.8 Associated Visiongain Reports
  • 1.9 About Visiongain

2. Introduction to Gene Therapy

  • 2.1 What is Gene Therapy?
  • 2.2 Types of Gene Therapy
  • 2.3 Products Excluded from the Report
  • 2.4 Gene Therapy Vectors

3. Gene Therapy World Market: Leading Treatments and Forecasts, 2016-2027

  • 3.1 The World Market for Gene Therapy: Overview of Products
  • 3.2 Gendicine (rAd-p53) - The First Gene Therapy to Market
  • 3.3 Oncorine: Growth is Hindered by Certain Factors
  • 3.4 Neovasculgen: Russiaés First Gene Therapy
    • 3.4.1 Neovasculgen: Historical Performance and Revenue Forecast, 2016-2027
  • 3.5 Glybera: A Drug with Promise
    • 3.5.1 Glybera: Pricing Ends the Dream to Become a Blockbuster Product

4. Gene Therapy World Market and Disease Submarkets, 2016-2027

  • 4.1 The Global Market for Gene Therapy Drug Treatments in 2016
  • 4.2 Gene Therapy Market Forecast, 2016-2027
  • 4.3 Gene Therapy for Cancer
    • 4.3.1 Clinical Trials for Cancer
    • 4.3.2 The Cancer Gene Therapy Treatment Submarket Forecast 2016-2027
  • 4.4 Gene Therapy for Rare Diseases
    • 4.4.1 The Rare Disease Treatment Submarket Forecast 2016-2027
  • 4.5 Gene Therapy for Cardiovascular Diseases
    • 4.5.1 The Cardiovascular Disease Treatment Submarket Forecast 2016-2027
  • 4.6 Gene Therapy for Ophthalmologic Diseases
    • 4.6.1 Advanced Stage Gene Therapies for Ophthalmologic Diseases
    • 4.6.2 The Ophthalmologic Disease Treatment Submarket Forecast 2016-2027
  • 4.7 Gene Therapy for Other Diseases
    • 4.7.1 The Other Disease Treatment Submarket Forecast 2016-2027
  • 4.8 Changing Market Shares: Cancer Disease Gene Therapies Will Dominate and Become Market Leader

5. Companies of Interest in the Gene Therapy Market: Robust Pipelines Will Yield Revenue in the Future

  • 5.1 UniQure- the First Commercial Stage Gene Therapy Company in the West
  • 5.2 Biogen - Focusing on Ophthalmologic and Rare Disease Gene Therapies
  • 5.3 Bluebird Bio: Gene Editing Technology
  • 5.4 Spark Therapeutics- Strong Change to Become the First Company with Marketed Gene Therapy in the US
  • 5.5 Applied Genetic Technologies Corporation: Specialisation in Ophthalmologic Diseases
  • 5.6 Oxford Biomedica: Collaboration as a Strategy
  • 5.7 GenSight Biologics - Novel Mitochondrial Technology Platform
  • 5.8 Gene Therapy and Big Pharma: Collaborations

6. R&D Pipeline Analysis and Forecasts, 2016-2027

  • 6.1 Pipeline
  • 6.2 Pipeline Analysis
  • 6.3 GSK2696273 - GSK
  • 6.4 Collategene (AMG0001) - AnGes MG/Vical
  • 6.5 BC-819 - BioCancell
  • 6.6 BC-821 - BioCancell
  • 6.7 Lenti-D - Bluebird Bio
  • 6.8 LentiGlobin (LentiGlobin BB305) - Bluebird Bio
  • 6.9 SPK-RPE65 - Spark Therapeutics
  • 6.10 SPK-CHM - Spark Therapeutics
  • 6.11 SPK-FIX - Spark Therapeutics/Pfizer
  • 6.12 SPK-TPP1- Spark Therapeutics
  • 6.13 Invossa (TissueGene-C) - TissueGene Inc/Kolon Life Science
  • 6.14 VM202-DPN - ViroMed
  • 6.15 Important Pipeline Technology Developments
  • 6.16 The Future of the Gene Therapy Pipeline

7. Qualitative Analysis of the Gene Therapy Market, 2017-2027

  • 7.1 SWOT Analysis of the Gene Therapy Treatment Market, 2017
  • 7.2 Strengths: A Vast Pipeline for a Wide Range of Indications
  • 7.3 Weaknesses: Low Patient Populations Cannot Sustain Long-Term Growth
  • 7.4 Opportunities and Threats for the Gene Therapy Drug Market, 2017-2027
  • 7.5 Opportunities: Collaborations and Novel Technologies Will Pave the Way
  • 7.6 Threats: Expensive Drugs with Strict Regulations
  • 7.7 National Markets: Regulation of the Gene Therapy Market
    • 7.7.1 Gene Therapy Regulations: Evolving with the Market
    • 7.7.2 US Regulations: Strict Regulation of a Cautious Market
    • 7.7.3 EU Regulations: One Approval So Far
    • 7.7.4 Japanese Regulations: A Rigorous Process

8. Conclusions

  • 8.1 The World Gene Therapy Treatment Market: Current World Outlook
    • 8.1.1 Leading Gene Therapy Treatment Submarkets and Products, 2016-2027
    • 8.1.2 Driver for Growth to 2027: A Vast Pipeline of Gene Therapy Products
    • 8.1.3 Leading Regional Markets and Companies: Partnerships Will Achieve Success
  • 8.2 The Future of the Gene Therapy Treatment Market

Appendices

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain report evaluation form

List of Tables

  • Table 1.1 Foreign Currency Exchange Rates Utilised: Exchange Rate to $US, 2015, 2016, and 2017
  • Table 3.1 Approved Gene Therapies, 2016
  • Table 3.2 Neovasculgen Historical Revenue Comparisons, Revenue ($m), AGR (%), 2013-2016
  • Table 3.3 Neovasculgen Forecast, Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 4.1 Leading Gene Therapy Drugs by Revenue ($m), 2016
  • Table 4.2 World Market Forecasts for Gene Therapy Drugs by Indication, Market Sizes ($m), Annual Growth Rates (%), CAGR (%), 2016-2027
  • Table 4.3 Selected Anti-Angiogenic Gene Therapy Using a Non-Viral Vector, 2016
  • Table 4.4 Selected Anti-Angiogenic Gene Therapy Using a Retroviral Vector, 2016
  • Table 4.5 Selected Anti-Angiogenic Gene Therapy Using an Adenoviral Vector, 2016
  • Table 4.6 Selected Anti-Angiogenic Gene Therapy Using an Adeno-Associated Virus Vector, 2016
  • Table 4.7 Selected Anti-Angiogenic Gene Therapy Using Lentiviral Vector, 2016
  • Table 4.8 Selected Cancer Gene Therapies in Phase 2 and Phase 3 Clinical Trial Development, 2016
  • Table 4.9 Selected Cancer Gene Therapies in Phase 1 and Phase 1/2 Clinical Trial Development, 2016
  • Table 4.10 Global Gene Therapy Market: Revenue ($m) and Market Shares (%) by Indication, 2016
  • Table 4.11 Global Market Forecast for Cancer Gene Therapies: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
  • Table 4.12 Global Gene Therapy Market: Revenue ($m) and Market Shares (%) by Indication, 2017
  • Table 4.13 Rare Diseases Gene Therapy Pipeline, 2016
  • Table 4.14 Global Market Forecast for Rare Disease Gene Therapies: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
  • Table 4.15 Cardiovascular Gene Therapy Pipeline, 2016
  • Table 4.16 Global Market Forecast for Cardiovascular Disease Gene Therapies: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
  • Table 4.17 Preclinical Ophthalmologic Pipeline, 2016
  • Table 4.18 Clinical Ophthalmologic Pipeline, 2016
  • Table 4.19 Additional Products in the Clinical Ophthalmologic Pipeline, 2016
  • Table 4.20 Global Market Forecast for Ophthalmologic Disease Gene Therapies: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
  • Table 4.21 Global Market Forecast for Other Disease Gene Therapies: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2016-2027
  • Table 4.22 Global Market Forecast for Gene Therapies by Indication: Market Shares (%), 2016-2021
  • Table 4.23 Global Market Forecast for Gene Therapies by Indication: Market Shares (%), 2022-2027
  • Table 5.1 uniQure Pipeline, 2016
  • Table 5.2 Spark Therapeutics Collaborations, 2016
  • Table 5.3 Selected Big Pharma Collaborations in Gene Therapy, 2016
  • Table 6.1 Promising Gene Therapies in Development, 2016
  • Table 6.2 Gene Therapies in Phase 3, 2016
  • Table 6.3 GSK2696273 Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2027
  • Table 6.4 Collategene Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2027
  • Table 6.5 BC-819 Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2027
  • Table 6.6 Lenti-D Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2027
  • Table 6.7 SPK-RPE65 Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2027
  • Table 6.8 Invossa Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2027
  • Table 7.1 Strengths and Weaknesses of the Gene Therapy Drug Treatment Market, 2017
  • Table 7.2 Gene Therapy Pipeline for Neurodegenerative Diseases, 2016
  • Table 7.3 Gene Therapy Pipeline for Metabolic Diseases, 2016
  • Table 7.4 Gene Therapy Pipeline for Musculoskeletal Diseases, 2016
  • Table 7.5 Gene Therapy Pipeline for Viral Diseases, 2016
  • Table 7.6 Opportunities and Threats of the Gene Therapy Drug Market, 2017
  • Table 7.7 Clinical Trials for Standard Drug Development Versus Orphan Drug Development, 2016
  • Table 8.1 Global Gene Therapy Drug Market Forecasts by Indication: Market Size ($m), Market Share (%), CAGR (%), 2016, 2021 and 2027

List of Figures

  • Figure 1.1 Global Gene Therapy Treatment Market Segmentation Overview, 2016
  • Figure 2.1 Vectors Used in Gene Therapy Clinical Trials, 2016
  • Figure 3.1 Neovasculgen Forecast, Revenue ($m), 2016-2027
  • Figure 4.1 Gene Therapy World Market Forecast, Market Size ($m), AGR (%), 2016-2027
  • Figure 4.2 Cancer Gene Therapy Pipeline by Phase of Development, 2016
  • Figure 4.3 Global Gene Therapy Market: Market Shares (%) by Indication, 2016
  • Figure 4.4 Global Market Forecast for Cancer Gene Therapies: Revenue ($m), 2016-2027
  • Figure 4.5 Global Gene Therapy Market: Market Shares (%) by Indication, 2017
  • Figure 4.6 Rare Diseases Gene Therapy Pipeline by Phase of Development, 2016
  • Figure 4.7 Global Market Forecast for Rare Disease Gene Therapies: Revenue ($m), 2016-2027
  • Figure 4.8 Cardiovascular Gene Therapy Pipeline by Phase of Development, 2016
  • Figure 4.9 Global Market Forecast for Cardiovascular Disease Gene Therapies: Revenue ($m), 2016-2027
  • Figure 4.10 Global Market Forecast for Ophthalmologic Disease Gene Therapies: Revenue ($m), 2016-2027
  • Figure 4.11 Global Market Forecast for Other Disease Gene Therapies: Revenue ($m), 2016-2027
  • Figure 4.12 Global Market for Gene Therapy Drugs: Market Shares by Indication (%), 2021
  • Figure 4.13 Global Market for Gene Therapy Drugs: Market Shares by Indication (%), 2027
  • Figure 6.1 Gene Therapies in Clinical Development by Phase, 2016
  • Figure 6.2 GSK2696273 Forecast, Revenue ($m), 2016-2027
  • Figure 6.3 Collategene Forecast, Revenue ($m), 2016-2027
  • Figure 6.4 BC-819 Forecast, Revenue ($m), 2016-2027
  • Figure 6.5 Lenti-D Forecast, Revenue ($m), 2016-2027
  • Figure 6.6 SPK-RPE65 Forecast, Revenue ($m), 2016-2027
  • Figure 6.7 Invossa Forecast, Revenue ($m), 2016-2027
  • Figure 8.1 Gene Therapy Drug Treatment Market Forecast by Indication: Market Sizes ($m), 2016, 2021, and 2027

Companies Listed

  • 4DMT (4D Molecular Therapeutics)
  • Abeona
  • AGTC (Applied Genetics Technologies Corporation)
  • AMT (Amsterdam Molecular Therapeutics)
  • AnGes MG
  • Asklepios BioPharma
  • AstraZeneca
  • Audentes Therapeutics
  • Avalanche Biotech
  • Bayer Healthcare
  • Beijing Northland Biotech Co
  • Benda Pharmaceutical
  • Benitec Biopharma
  • BioCancell
  • Biogen
  • Biogen Idec
  • Bluebird Bio
  • BMS (Bristol-Myers Squibb)
  • Broad Institute/Whitehead Institute
  • Celgene
  • Cell Therapy Catapult
  • Cellectis
  • Chiesi Farmaceutici
  • Clearside Biomedical
  • Convergence Pharmaceuticals
  • Daiichi Sankyo
  • Dimension Therapeutics
  • Editas Medicine
  • Fondazione Telethon
  • Francis Crick Institute
  • Genable Technologies Ltd
  • Genethon
  • GenSight Biologics
  • GenVec
  • Google
  • GSK (GlaxoSmithKline)
  • Henry Ford Health System
  • HSCI (Human Stem Cells Institute)
  • HSR-TIGET (San Raffaele Telethon Institute for Gene Therapy),
  • ImaginAb
  • Immune Design Corp
  • InoCard
  • Inovio
  • Intellia Therapeutics
  • Invetech
  • Kite Pharma
  • Kolon Group
  • Kolon Life Science
  • Lysogene
  • Mitsubishi Tanabe Pharma Corporation
  • Neuralgene
  • NightstaRx
  • Northwestern Memorial Hospital
  • Novartis
  • OXB (Oxford Biomedica)
  • Pfizer
  • PNP Therapeutics
  • Precision Genome Engineering Inc aka Pregenen
  • ProNai
  • Protek Group
  • Raffaele Hospital
  • REGENX Biosciences
  • Renova Therapeutics
  • Roche
  • Roszdravnadzor
  • Sangamo Biosciences
  • Sanofi
  • Sarepta Therapeutics
  • Shanghai Sunway Biotech
  • Shenzhen SiBiono GeneTech
  • Sotex Pharm Firm
  • Spark Therapeutics
  • SynerGene Therapeutics
  • Takara Bio
  • TAP Biosystems
  • Thermo Fisher Scientific
  • TissueGene
  • ToolGen
  • UC Berkeley
  • UC San Francisco
  • uniQure
  • US Business Innovation Network
  • Vertex Pharmaceuticals
  • Vical Incorporated
  • ViroMed
  • VM Biopharma
  • Voyage Therapeutics

Organizations Mentioned in the Report

  • ASCO (American Society of Clinical Oncology)
  • ASI (Agency for Strategic Initiatives)
  • CAT (Committee for Advanced Therapies)
  • CBER (Center for Biologics Evaluation and Research)
  • CHMP (Committee for Medicinal Products for Human Use)
  • CHOP (The Childrenés Hospital of Philadelphia)
  • DCGI (Drugs Controller General of India)
  • DHHS (Department of Health and Human Services)
  • EMA (European Medicines Agency)
  • FDA (US Food and Drug Administration)
  • INSERM (Institut National de la Santé et de la Recherche Médicale)
  • IRB (Institutional Review Boards)
  • MFDS (Korean Ministry of Food and Drug Safety)
  • MHLW (Ministry of Health, Labour, and Welfare)
  • MHRA (Medicines and Healthcare Products Regulatory Agency)
  • Ministry of Health Commission
  • NHS (National Health Service)
  • NICE (the National Institute for Health and Care Excellence)
  • NIH (National Institutes of Health)
  • OHRP (Office for Human Research Protections)
  • PMDA (Pharmaceuticals and Medical Devices Agency)
  • RCGM (Review Committee of Genetic Manipulation)
  • Russian Ministry of Healthcare and Social Development
  • SFDA (State Food and Drug Administration of China)
  • SMC (Scottish Medicines Consortium)
  • The Fund for Promotion of Small Innovative Enterprises in Science and Technology
  • The IGI (Innovative Genomics Initiative)
  • The Innovative Genomics Initiative
  • The Walter and Eliza Hall Institute
  • The Wellcome Trust Sanger Institute
  • WFH (World Federation of Hemophilia)
  • WHO (World Health Organization)
Back to Top